Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.047
Sell
RSI(14)
38.151
Neutral
STOCH(KDJ)(9,3,3)
24.051
Buy
ATR(14)
0.109
High Vlolatility
CCI(14)
-92.207
Neutral
Williams %R
68.561
Sell
TRIX(12,20)
-0.772
Sell
StochRSI(14)
100.000
Buy
Microbot Medical Inc
MBOT1.760USD
+0.140+8.64%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
115.87MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Microbot Medical Inc
Currency: USD Updated: 2026-02-06Key Insights
Microbot Medical Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 149 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Microbot Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Microbot Medical Inc Highlights
StrengthsRisks
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Undervalued
The company’s latest PE is -3.91, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 10.55M shares, increasing 28.94% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.33M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.02.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
7.500
Target Price
+362.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Microbot Medical Inc is 5.51, ranking 354 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.75
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Microbot Medical Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Microbot Medical Inc is 7.00, ranking 189 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.91, which is -84.26% below the recent high of -0.62 and -99.26% above the recent low of -7.79.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 149/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Microbot Medical Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.75, with a high of 12.00 and a low of 5.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
7.500
Target Price
+362.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Microbot Medical Inc
MBOT
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Microbot Medical Inc is 6.46, ranking 241 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.12 and the support level at 1.50, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.740
Buy
MA10
1.815
Sell
MA20
1.949
Sell
MA50
2.110
Sell
MA100
2.371
Sell
MA200
2.601
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Microbot Medical Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 15.70%, representing a quarter-over-quarter increase of 64.38%. The largest institutional shareholder is The Vanguard, holding a total of 3.33M shares, representing 4.96% of shares outstanding, with 132.42% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
CIBC Private Wealth Management
Susquehanna International Group, LLP
Heights Capital Management, Inc.
DNB Asset Management AS
Geode Capital Management, L.L.C.
BlackRock Institutional Trust Company, N.A.
UBS Financial Services, Inc.
State Street Investment Management (US)
The Informed Momentum Company LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Microbot Medical Inc is 3.58, ranking 135 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.30
VaR
+6.93%
240-Day Maximum Drawdown
+64.00%
240-Day Volatility
+99.96%
Return
Best Daily Return
60 days
+21.81%
120 days
+22.95%
5 years
+159.29%
Worst Daily Return
60 days
-9.90%
120 days
-15.56%
5 years
-33.91%
Sharpe Ratio
60 days
-0.43
120 days
-0.95
5 years
+0.21
Risk Assessment
Maximum Drawdown
240 days
+64.00%
3 years
+76.05%
5 years
+90.77%
Return-to-Drawdown Ratio
240 days
+0.20
3 years
-0.10
5 years
-0.17
Skewness
240 days
+1.04
3 years
+9.06
5 years
+9.76
Volatility
Realised Volatility
240 days
+99.96%
5 years
+104.98%
Standardised True Range
240 days
+11.50%
5 years
+12.52%
Downside Risk-Adjusted Return
120 days
-173.95%
240 days
-173.95%
Maximum Daily Upside Volatility
60 days
+65.75%
Maximum Daily Downside Volatility
60 days
+45.77%
Liquidity
Average Turnover Rate
60 days
+6.30%
120 days
+7.09%
5 years
--
Turnover Deviation
20 days
-2.19%
60 days
-29.56%
120 days
-20.72%
Peer Comparison
Biotechnology & Medical Research
Microbot Medical Inc
MBOT
5.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
